Aurobindo Pharma gets Form 483 from USFDA with 1 observation

The United States Food and Drug Administration (US FDA) inspected Unit VI - B, a Formulation manufacturing facility of Aurobindo Pharma Ltd, situated at Chitkul Village, Patancheru Mandal, Sangareddy District, Telangana, from September 22 to September 29, 2023.

At the end of the inspection, a 'Form 483' was issued with 1 observation which is procedural in nature. We will respond to the US FDA within the stipulated timelines and work closely with US FDA to close the observation at the earliest.

Balaxi Pharmaceuticals completes acquisition of Balaxi Healthcare Ecuador

Balaxi Pharmaceuticals Limited has successfully completed the acquisition of 100% shareholding in Balaxi Healthcare Ecuador S.A.S., an Ecuadorian Company. After completion of the acquisition, Balaxi Healthcare Ecuador S.A.S. has become a Wholly Owned Subsidiary of the Company.